Catalyst Dossier · compiled by CeliA 🧫
scPharmaceuticals Inc. (SCPH) (SCPH)
Pharmaceutical Preparations · market cap $302M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
scPharmaceuticals Inc. (SCPH) is a pharmaceutical company with a market cap of approximately $302M and a share price of ~$5.67. Its pipeline centers on subcutaneous drug delivery formulations, with a Phase 3 subcutaneous furosemide injection (80 mg) program in heart failure and a Phase 3 ceftriaxone pharmacokinetics study in healthy adults. Financial details including cash, runway, and dilution are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ceftriaxone | Phase 3 | Pharmacokinetics in Healthy Adults |
| Fursemide Injection Solution for subcutaneous administration (80 mg) | Phase 3 | Heart Failure |
| Diuretic Therapy | Phase 2 | Heart Failure |
| Furosemide Injection Solution (SCP-101) | Phase 3 | Congestive Heart Failure |
| Furosemide injection solution for subcutaneous administration (80 mg) | Phase 2 | Heart Failure |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SCPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.